IBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-03-31 was 1.00K shares.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2020-06-30 was 135.64K shares.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-09-30 was 120.00K shares, a 98.55% decline year-over-year.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2015-06-30 was -1.61M shares.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2026 was 0.00 shares, a 100.00% decline from fiscal 2025.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 73.10K shares.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares, a 100.00% decline from fiscal 2022.
- IBIO, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 3.38K shares, a 57.43% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 0.00 shares 10-K · filed 2026-08-28 | |
| 2025-06-30 | 73.10K shares 10-K · filed 2026-08-28 | |
| 2023-06-30 | 0.00 shares 10-K · filed 2023-09-27 | |
| 2022-06-30 | 3.38K shares 10-K · filed 2023-09-27 | |
| 2021-06-30 | 2.15K shares 10-K · filed 2022-10-11 | |
| 2021-03-31 | 1.00K shares 10-Q · filed 2021-05-17 | |
| 2020-06-30 | 135.64K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | 139.39K shares 10-K · filed 2021-09-28 |
| 2015-09-30 | 120.00K shares 10-Q · filed 2016-02-22 | 146.69K shares derived: sum of 4 quarters · filed 2016-10-13 |
| 2015-06-30 | -1.61M shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-10-13 | 26.69K shares 10-K · filed 2016-10-13 |
| 2015-03-31 | 0.00 shares 10-Q · filed 2015-05-15 | |
| 2014-12-31 | 1.64M shares 10-Q · filed 2015-02-24 | |
| 2014-09-30 | 8.30M shares 10-Q · filed 2014-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |